A new paradigm for mental health in Australia: Medicinal psilocybin & MDMA to assist psychotherapy




Mental illness in Australia - prevalence

- One in five (4.8 million) Australians aged 16-85 have current and chronic mental health or behavioural condition.
- Over **45%** of Australians will experience mental illness in their lifetime.
- Most common mental illnesses in Australia are depression, anxiety, and substance use disorders (often occurring together).



Mental illness in Australia - costs

- Adults with mental or behavioural illness nearly twice as likely to be unemployed or out of labour force (37.8%) than others (20.5%).
- Direct costs of mental illness at least \$28.6 billion annually, 2.2% of Australian GDP (in 2011).



Medibank Private Limited and Nous Group. (2013). The Case for Mental Health Reform in Australia: A Review of Expenditure and System Design.


Mental illness treatment outcomes

- In spite of vast global effort to understand and treat mental illness over decades, effectiveness of treatment remains inadequate.
- Eg: only 40 to 60% of depressed individuals respond to chemical or talk therapies, majority responders continue to experience sub-diagnostic symptoms, 50% to 80% relapse when treatment stops.
 - With soaring rates, debilitating cost to life and economy, inadequate treatment options, and increasing rates of major mental illnesses, new approaches are urgently needed.

Belsher, G., & Costello, C. G. (1988). Relapse after recovery from unipolar depression: a critical review. Psychological bulletin, 104(1), 84. Hollon, S. D., Thase, M. E., & Markowitz, J. C. (2002). Treatment and prevention of depression. Psych Science in the Public Interest, 3(2), 39-77. Judd, L. L. (1997). The clinical course of unipolar major depressive disorders. Archives of General Psychiatry, 54(11), 989.

What is Psychedelic-assisted Psychotherapy?

- 'Talk-therapy' alongside ingestion of medicinal psilocybin or MDMA.
- Therapy program with three distinct phases: (1) preparation; (2) acute medicinal experience; (3) integration.
- Approach emphasis: 'set and setting'; non-avoidance and curiosity; non-directive support during acute stage; respect for process.
- Experience commonly includes substantial increases in empathy, self-compassion, insightfulness, connectedness, meaningfulness.
- Facilitated by clinical psychologists and psychiatrists within appropriate medical facilities (MDs, nurses, equipment), but decorated as a living room to satisfy adequate 'setting'





30-year political suppression of psychedelic research and treatment

John Ehrlichman (senior Nixon aide) on War on Drugs:

"The Nixon campaign in 1968, and the Nixon White House after that, had two enemies: the anti-war left and black people. You understand what I'm saying? We knew we couldn't make it illegal to be either against the war or black, but by getting the public to associate the hippies with marijuana and blacks with heroin, and then criminalizing both heavily, we could disrupt those communities. We could arrest their leaders, raid their homes, break up their meetings, and vilify them night after night on the evening news. **Did we know we were lying about the drugs? Of course we did**."

- Psychedelic use criminalised (Schedule 1)
- All research funding ceased
- Leary: 'most dangerous man' in America




The Psychedelic Renaissance


Dr Stanislav Grof, Psychiatrist and pioneering psychedelic researcher:

"It does not seem to be an exaggeration to say that psychedelics, used responsibly and with proper caution, would be for psychiatry what the microscope is for biology and medicine or the telescope is for astronomy."

Current or recently completed trials:

- Psilocybin 32 trials
- LSD 8 trials
- Ayahuasca 1 trial
- Ibogaine 4 trials
- Salvinorin A 4 trials
- MDMA 48 trials





Psilocybin and MDMA Results


- Medicinal MDMA effective for Post-Traumatic Stress Disorder (PTSD).
- Medicinal psilocybin and other 'classical psychedelics' (e.g., LSD, ayahuasca, iboga) effective for depression, anxiety, addiction.
- Phase 1 and 2 trial results have been remarkable in terms of the strength, speed, and enduring outcomes of the treatment effect.
- Only 2-3 dosed sessions with lasting impact (contrast conventional treatments: involves daily medication or weekly psychotherapy over longterm)
- Due to compelling results and urgent need, FDA has designated medicinal psilocybin and MDMA with 'breakthrough therapy' status (fast-tracked).
- Current Phase 3 trials underway: positive results will lead to schedule change and prescription regulation.

Johnson, M et al. (2014). 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28-11:983-992. Ross et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30-12:1165-1180. Carhart-Harris et al. (2016). Psilocybin with psychological support for treatment-resistant depression. The Lancet, 3-7:619-627. Nutt, D. J., King, L. A., & Phillips, L. D. (2010). Drug harms in the UK: a multicriteria decision analysis. The Lancet, 376(9752), 1558-1565.

Remarkable Treatment Outcomes

- Most effective treatments for mental illness show effect sizes in the order of d=0.5 (a measure of treatment benefit, where 0.2='small'; 0.5='medium'; 0.8='large')
- Psychedelic-assisted Psychotherapy effects are 'off the charts'
 - Psilocybin for depression: *d*=2.0-3.1
 - Psilocybin for end-of-life distress: *d*=0.8-1.6
 - Psilocybin for alcoholism: *d*=1.2-1.4
 LSD for end-of-life distress: *d*=1.1-1.2
 MDMA for PTSD: *d*=1.17-1.24

Schenberg, E. E. S. (2018). Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development. *Frontiers in pharmacology*, 9, 733. Petri, G., Expert, P., Turkheimer, F., Carhart-Harris, R., Nutt, D., Hellyer, P. J., & Vaccarino, F. (2014). Homological scaffolds of brain functional networks. *Journal* of The Royal Society Interface, 11(101), 20140873.




MDMA-assisted Psychotherapy

- MAPS Phase 2 trials: 107 participants, all treatment-resistant (average duration of PTSD=17.8 years); 56% no longer qualified for PTSD at 2month follow-up, 68% had no PTSD at 12-months.
- Substantially better than psychotherapy alone.
- Sustained long-term benefits up to at least 4 years.
- All participants reported at least some persisting benefit.
- No negative effects on cognitive function; clinical studies of MDMA in nearly 800 participants, only 1 serious adverse event.




Psilocybin-assisted Psychotherapy Sustained Outcomes



Griffiths, R. R. et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. *Journal of psychopharmacology*, *30*(12), 1181-1197.

Safety of Psychedelic use



Nutt, D. J., King, L. A., & Phillips, L. D. (2010). Drug harms in the UK: a multicriteria decision analysis. The Lancet, 376(9752), 1558-1565. Krebs and Johansen, 2013; Hendricks et al., 2014, 2015; Johansen and Krebs, 2015.

- Classical psychedelics: negligible physiological harm/toxicity, very low abuse potential.
- With proper clinical support, the minimal psychological risks are almost completely mitigated.
- (An aside: no increase in risk for mental ill-health or addiction with unsupervised use of classical psychedelics compared with non-use.)

Example institutions with active psychedelic research program



14

Example empirical publications in leading journals

ORIGINAL INVESTIGATION

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Journal of Humanistic Psycho 2017, Vol. 57(5) 520-5

sagepub.com/journalsPermissions.na DOI: 10.1177/002216781770958

journals.sagepub.com/home/jh

C The Author(s) 20 Reprints and permission

(\$)SAG

5

R. R. Griffiths · W. A. Richards · U. McCann · R. Jesse

Article

Patients' Accounts of Increased "Connectedness" and "Acceptance" After Psilocybin for **Treatment-Resistant** Depression

Rosalind Watts¹, Camilla Day¹, Jacob Krzanowski¹, David Nutt¹, and Robin Carhart-Harris¹

CellPress

Original Paper

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

Roland R Griffiths^{1,2}, Matthew W Johnson¹, Michael A Carducci³, Annie Umbricht¹, William A Richards¹, Brian D Richards¹, Mary P Cosimano¹ and Margaret A Klinedinst¹

Neural correlates of the LSD experience revealed by multimodal neuroimaging

Robin L. Carhart-Harris^{a,1}, Suresh Muthukumaraswamy^{b,c,d}, Leor Roseman^{a,e,2}, Mendel Kaelen^{a,2}, Wouter Droog^b, Kevin Murphy^b, Enzo Tagliazucchi^{1,g}, Eduardo E. Schenberg^{a,h,j}, Timothy Nestⁱ, Csaba Orban^{a,e}, Robert Leech^e, Luke T. Williams^a, Tim M. Williams^k, Mark Bolstridge^a, Ben Sessa^{a,I}, John McGonigle^a, Martin I. Sereno^m, David Nicholsⁿ, Peter J. Hellyer^e, Peter Hobden^b, John Evans^b, Krish D. Singh^b, Richard G. Wise^b, H. Valerie Curran^o, Amanda Feilding^p, and David J. Nutta

^aCentre for Neuropsychopharmacology, Department of Medicine, Imperial College London, W12 0NN, London, United Kingdom; ^bDepartment of Psychology, Cardiff University Brain Research Imaging Centre, CF10 3AT, Cardiff, United Kingdom; 'School of Pharmacy, University of Auckland, 1142 Auckland, New Zealand; ^dSchool of Psychology, University of Auckland, 1142 Auckland, New Zealand; ^eComputational, Cognitive and Clinical Neuroscience Laboratory, Department of Medicine, Imperial College London, W12 0NN, London, United Kingdom; ¹Institute of Medical Psychology, Christian Albrechts iversity, 24118 Kiel, Germany; ⁹Brain Imaging Center and Neurology Department, Goethe University, 60528 Frankfurt am Main, Germany; ^hDep

Psychopharm



ournal of Psychopharmacology 2016, Vol. 30(12) 1181-1197

DOI: 10.1177/0269881116675513

© The Author(s) 2016

Reprints and permissions

œ 0

jop.sagepub.com

(S)SAGE

Enhanced Repertoire of Brain Dynamical States **During the Psychedelic Experience**

Enzo Tagliazucchi,¹* Robin Carhart-Harris,² Robert Leech,³ David Nutt,² and Dante R. Chialvo⁴

¹Neurology Department and Brain Imaging Center, Goethe University, Frankfurt am Main, German ²Imperial College London, Centre for Neuropsychopharmacology, Division of Experimental Medicine, London, United Kingdom sagepub.co.uk/journalsPermissions.nav ³Computational, Cognitive and Clinical Neuroimaging Laboratory (C3NL), Division of Brain Sciences, Imperial College London, United Kingdom ⁴Consejo Nacional de Investigaciones Científicas y Tecnologicas (CONICET), Buenos Aires, Argentina

Implications for psychedelic-assisted psychotherapy: a functional magnetic resonance imaging study with psilocybin

R. L. Carhart-Harris, R. Leech, T. M. Williams, D. Erritzoe, N. Abbasi, T. Bargiotas, P. Hobden, D. J. Sharp, J. Evans, A. Feilding, R. G. Wise and D. J. Nutt

THE LANCET Psychiatry

Articles

Psilocybin with psychological support for treatment-resistant $\rightarrow M$ is (depression: an open-label feasibility study

oa Robin L. Carhart-Harris, Mark Bolstridge, James Rucker*, Camilla M J Day*, David Erritzoe, Mendel Kaelen, Michael Bloomfield, James A Rickard, Ben Forbes, Amanda Feildina, David Taylor, Steve Pillina, Valerie H Curran, David I Nutt

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

Robin L. Carhart-Harris^{a,b}, David Erritzoe^{a,c}, Tim Williams^b, James M. Stone^a, Laurence J. Reed^a, Alessandro Colasanti^a, Robin J. Tyacke^a, Robert Leech^d, Andrea L. Malizia^b, Kevin Murphy^e, Peter Hobden^e, John Evans^e, Amanda Feilding^f, Richard G. Wise^e, and David J. Nutt^{a,b,1}

Pilot study of the 5-HT₂₄R agonist psilocybin in the treatment of tobacco addiction

Psychedelics Promote Struc Matthew W Johnson¹, Albert Garcia-Romeu¹, Mary P Cosimano and Roland R Griffiths^{1,2} and Functional Neural Plasti

Calvin Ly,¹ Alexandra C. Greb,¹ Lindsay P. Cameron,² Jonathan M. Wong,² Eden V. Barragan,² Paige C. Wilson,³ Kyle F. Burbach,⁴ Sina Soltanzadeh Zarandi,¹ Alexander Sood,⁵ Michael R. Paddy,³ Whitney C. Duim,¹ Megan Y. Dennis,^{4,6,7} A. Kimberley McAllister,^{5,8,9} Kassandra M. Ori-McKenney,³ John A. Gray,^{5,8} and David E. Olson^{1,5,6,10,*} ¹Department of Chemistry, University of California, Davis, Davis, CA 95616, USA ²Neuroscience Graduate Program, University of California, Davis, Davis, CA 95618, USA

³Department of Molecular and Cellular Biology, University of California, Davis, Davis, CA 95616, USA ⁴Genome Center, University of California, Davis, Davis, CA 95616, USA ⁵Center for Neuroscience, University of California, Davis, Davis, CA 95618, USA ⁶Department of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, Sacramento, CA 95817, USA


⁷MIND Institute, University of California, Davis, Sacramento, CA 95817, USA

⁸Department of Neurology, School of Medicine, University of California, Davis, Sacramento, CA 95817, USA ⁹Department of Neurobiology, Physiology, and Behavior, University of California, Davis, Davis, CA 95616, USA

Results that are Breaking Through

- FDA '**breakthrough therapy**' designation for medicinal psilocybin and MDMA: only given to treatments for serious conditions that shows signs of being substantially better than available treatment.
- Israeli Ministry of Health 'compassionate use' decision to provide MDMA-assisted psychotherapy to PTSD sufferers outside of a clinical trial, due to lack of effective alternatives.
- Denver (Colorado) will vote whether to decriminalise psilocybin possession in May 2019, and Oregon state will vote whether to fully legalise psilocybin in 2020

The Universe of FDA Drug Approval



Source: Wong CH, Shaw K., Lo A. (2018) Estimation of clinical trial success rates and related parameters. Biostatistics (prepublished). Numbers from 2000 to 2015, with oncology excluded.

Psychedelic Research - Australia's first trial

- First in Australia: Psilocybin-assisted psychotherapy for treatment of Australian palliative care patients who are experiencing depression and anxiety.
- Double-blind, placebo-controlled trial, 30 participants.
- Recruitment commences first half of 2019.
- Trial site and team from St Vincent's Hospital, sponsored by PRISM, funded by Mind Medicine Australia and Vasudhara.











MIND MEDICINE

A registered charity (DGR-1 status) seeking to establish **safe and effective** psychedelic-assisted treatments for mental illness in Australia.

Operates as a nexus between medical practitioners, academia, government, regulatory bodies, philanthropists, and other partners.

Focus is wholly **clinical** - we do not advocate for recreational use, nor for changes to the law with respect to recreational use.



Core aims:

- **1. Reduce delay** between availability of adequate evidence and regulatory approval and implementation
- 2. Increase likelihood of **best practice** implementation following regulatory approval

Broad activities:

- Research
- Education and events

- Partnerships
- Regulation and policy development
- Training and accreditation

Who We Are

Board of Directors





Peter Hunt AM CHAIR

Tania de Jong AM DEPUTY CHAIR

Dr Simon Longstaff AO DIRECTOR

Monojit Ray DIRECTOR



Admiral Chris Barrie AC Prof David Castle DIRECTOR



Luke Mitchell DIRECTOR

Management

DIRECTOR



Dr Paul Liknaitzky **Executive Officer**



Melissa Warner **Education Officer**



Dr Martin Williams Scientific Officer



Prof Avni Sali AM Surgeon and Academic, Integrative Medicine



Dr David Caldicott Patrycja Slawuta (USA) **Behavioural Scientist Emergency Medicine**





Dr Alex Wodak Physician

Dr Nigel Strauss Psychiatrist



MIND MEDICINE AUSTRALIA

Ambassadors

Advisory Panel

Consultant







Professor David Nutt (UK) Dr Rick Doblin (USA)

Dr Ben Sessa (UK)

Over 45% of Australians will experience a serious mental health illness during their lifetimes.

20

What are you going to do about it?



